Notably, Cortes and colleagues have shown that approximately half of the clinical cases of TKI resistance do not involve mutations in the BCR::ABL1 kinase domain, pointing to kinase-independent mechanisms playing a significant role in the resistance observed in CML [40]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.